The role of inflammation in cardiovascular disease

MY Henein, S Vancheri, G Longo… - International journal of …, 2022 - mdpi.com
Atherosclerosis is a chronic inflammatory disease, in which the immune system has a
prominent role in its development and progression. Inflammation-induced endothelial …

[HTML][HTML] Inflammation and cardiovascular disease: From mechanisms to therapeutics

A Alfaddagh, SS Martin, TM Leucker, ED Michos… - American journal of …, 2020 - Elsevier
Inflammation constitutes a complex, highly conserved cascade of molecular and cellular
events. Inflammation has been labeled as “the fire within,” is highly regulated, and is critical …

Targeting the CCL2–CCR2 axis for atheroprotection

MK Georgakis, J Bernhagen, LH Heitman… - European heart …, 2022 - academic.oup.com
Decades of research have established atherosclerosis as an inflammatory disease. Only
recently though, clinical trials provided proof-of-concept evidence for the efficacy of anti …

Atherogenic index of plasma and coronary artery disease in the adult population: a meta-analysis

J Wu, Q Zhou, Z Wei, J Wei, M Cui - Frontiers in Cardiovascular …, 2021 - frontiersin.org
Background: The atherogenic index of plasma (AIP), which is the logarithm of the ratio
between the triglyceride and high-density lipoprotein cholesterol (TG/HDL-C) concentrations …

Monomeric C-reactive protein in atherosclerotic cardiovascular disease: advances and perspectives

I Melnikov, S Kozlov, O Saburova, Y Avtaeva… - International journal of …, 2023 - mdpi.com
This review aimed to trace the inflammatory pathway from the NLRP3 inflammasome to
monomeric C-reactive protein (mCRP) in atherosclerotic cardiovascular disease. CRP is the …

Non-HDL cholesterol and residual risk of cardiovascular events in patients with ischemic heart disease and well-controlled LDL cholesterol: a cohort study

MK Hansen, MB Mortensen, KKW Olesen… - The Lancet Regional …, 2024 - thelancet.com
Background Identifying patients at high residual risk of atherosclerotic cardiovascular
disease (ASCVD) despite statin-treatment is of paramount clinical importance. We aim to …

[HTML][HTML] Clinical approach to the inflammatory etiology of cardiovascular diseases

M Ruscica, A Corsini, N Ferri, M Banach… - Pharmacological …, 2020 - Elsevier
Inflammation is an obligatory marker of arterial disease, both stemming from the
inflammatory activity of cholesterol itself and from well-established molecular mechanisms …

Synergistic effect of the commonest residual risk factors, remnant cholesterol, lipoprotein (a), and inflammation, on prognosis of statin-treated patients with chronic …

HH Liu, YL Guo, CG Zhu, NQ Wu, Y Gao, RX Xu… - Journal of Translational …, 2022 - Springer
Background Currently, remnant cholesterol (RC), lipoprotein (a)[Lp (a)], and inflammation
are considered the principal residual cardiovascular risk (RCVR) factors. This study sought …

Inflammation during percutaneous coronary intervention—prognostic value, mechanisms and therapeutic targets

B Tucker, K Vaidya, BJ Cochran, S Patel - Cells, 2021 - mdpi.com
Periprocedural myocardial injury and myocardial infarction (MI) are not infrequent
complications of percutaneous coronary intervention (PCI) and are associated with greater …

Systemic inflammation and health outcomes in patients receiving treatment for atherosclerotic cardiovascular disease

F Mazhar, AL Faucon, EL Fu, KE Szummer… - European Heart …, 2024 - academic.oup.com
Abstract Background and Aims The burden and outcomes of inflammation in patients with
atherosclerotic cardiovascular disease (ASCVD) are not well defined beyond the controlled …